The largest database of trusted experimental protocols

Atlantis t3 c18 column

Manufactured by Waters Corporation
Sourced in United States, Ireland

The Atlantis T3 C18 column is a reverse-phase high-performance liquid chromatography (HPLC) column. It utilizes a C18 stationary phase to separate a wide range of analytes based on their hydrophobic interactions. The column is designed for robust and reliable performance in routine HPLC applications.

Automatically generated - may contain errors

33 protocols using atlantis t3 c18 column

1

Purification and Identification of LEGCG

Check if the same lab product or an alternative is used in the 5 most similar protocols
Waters HPLC systems comprise a 1525 pump and a 2998 diode array detector (DAD) was used for analysis. The separation was performed by a 5 μm Waters Atlantis T3-C18 column (250 × 4.6 mm). The mobile phase was 0.1% acetic acid (A) and methanol (B) with a gradient program of 0−30 min, 40%−100% B linear gradient elution. The injection volume was 20 μL and the flow rate was 1 mL/min. The detection wavelength was set at 280 nm. A Thermo Scientific LCQ Ion-Trap Mass Spectrometer (Thermo Fisher Scientific, San Jose, CA, USA) with electrospray ionization (ESI) at positive mode was used for the HPLC-MS/MS analysis. The conditions were: Dry gas flow, 35 L/min; capillary voltage, 3.5 kV; nebulizer, 30 psi; collision energy, 16 eV; desolvation temperature, 400 °C.
To get purified LEGCG, Waters semi-preparative HPLC systems comprise a 600E pump and a 2998 DAD was used. The separation was carried out using a 19 mm Waters Atlantis OBD-C18 column (10 μm, 250 mm). The mobile phases were 0.1% acetic acid (A) and methanol (B). The gradient program was 0−30 min, 40%−100% B linear gradient elution, at a flow rate of 5 mL/min. The injection volume was 100 μL. The UV absorbance was detected at 280 nm. A Bruker Avance 500 MHz NMR spectrometer (Bruker Biospin GmbH, Rheinstetten, Germany) was carried out for the purified LEGCG to identify its molecular structure.
+ Open protocol
+ Expand
2

Quantification of DPC-Containing DNA

Check if the same lab product or an alternative is used in the 5 most similar protocols
To quantify DPC-containing DNA extracted from cells and to detect any potential RNA contamination, 1 μg aliquots of DNA were taken and digested to 2′-deoxynucleosides in the presence of phosphodiesterase I (120 mU), phosphodiesterase II (105 mU), DNase (35 U) and alkaline phosphatase (22 U) in 20 μL 10 mM Tris-HCl/15 mM ZnCl2 (pH 7.0) for 18 h at 37 °C. Quantitative analysis of dG in enzymatic digests was conducted by HPLC-UV on an Agilent Technologies 1100 HPLC system equipped with a diode array UV detector and an autosampler. Samples were loaded onto an Atlantis T3 C18 column (2.1 × 150 mm, 5 μm, from Waters Corporation, Milford, MA) and eluted with a gradient of 5 mM ammonium formate, pH 4.0 (A) and methanol (B). Solvent composition was changed linearly from 3 to 30% B over 15 min, increased further to 80% B over 3 min, held at 80% B for 1 min, and returned to 3% B over 2 min, where it was kept for the final 8 min of the HPLC run. UV absorbance was monitored at 260 nm. With this method, dG eluted as a sharp peak at 11.7 min (Figure S-1). dG amounts were determined by comparing HPLC peak areas to a calibration curve constructed by injecting known dG amounts.
+ Open protocol
+ Expand
3

HPLC Analysis of Compounds

Check if the same lab product or an alternative is used in the 5 most similar protocols
The HPLC analysis was conducted on an Agilent 1260 Infinity II HPLC system equipped with a binary pump, an autosampler, a thermostated column compartment, and a diode array detector (Agilent Technologies, Santa Clara, CA, USA). The compounds were separated on a Waters Atlantis® T3-C18 column (4.6 × 50 mm, 5 μm, Waters™, MA, USA) at 28 °C. The mobile phase consisted of 0.04% aqueous formic acid (A) and methanol (B) using a gradient program of 20–25% (B) in 0–13 min, 25–35% (B) in 13–20 min, and 35% (B) in 20–25 min. The flow rate was 1.0 mL min−1. The detection wavelength was 240 nm.
+ Open protocol
+ Expand
4

Structural Identification of Adducts via MS and NMR

Check if the same lab product or an alternative is used in the 5 most similar protocols
The structures of purified adducts were identified with mass spectrometry (MS) analysis and nuclear magnetic resonance (NMR). An X500R QTOF high-resolution mass spectrometer (HRMS; AB Sciex, MA, United States) was operated at 500°C, with a capillary voltage of 5.5 kV, drying gas and nebulizer gas pressure of 50 and 55 psi, respectively. The sample was separated on an Atlantis T3 C18 column (4.6 × 150 mm, 5 μm, Waters Corporation, Milford, US). The spectrum was scanned in positive ion mode and obtained over a mass range from 50 to 1,000 Da.
For NMR analysis, 10 mg of the purified adducts were dissolved in 0.55 mL of D2O (Lys-AA, GABA-AA 1, Gly-AA 1 and Gly-AA 2) or DMSO-d6 (Trp-AA and GABA-AA 2) (20 (link)). 1H, 13C, Dept 135 and two-dimensional NMR spectra were obtained using a Bruker 600 MHz Avance III NMR spectrometer.
+ Open protocol
+ Expand
5

Quantification of Five Quinoline Alkaloids

Check if the same lab product or an alternative is used in the 5 most similar protocols
Separation of the five QAs was
performed using an Atlantis T3 C18 column (i.d. = 100 mm × 2.1
mm and particle diameter = 3 μm; Waters) and 0.1% HFBA in water
and 0.1% HFBA in MeOH as mobile phases A and B, respectively (flow
rate: 0.5 mL min–1). The sample injection volume
was 5 μL, the column oven temperature was 35 °C, and the
autosampler temperature was set to 10 °C. The following gradient
elution program was used: 0–0.5 min, 95% A; 0.5–4.0
min, 0% A; 4.0–4.5 min, 0% A; and 4.5–5.0 min, 95% A.
The mass spectra were acquired in the multiple reaction monitoring
(MRM) mode using the following optimized parameters: dwell time =
0.3 ms per transition, capillary voltage = 2.5 kV, cone voltage =
20 V, source temperature = 150 °C, and desolvation temperature
= 500 °C. The nitrogen flow rates for the cone and desolvation
were 150 and 800 L h–1, respectively. Argon was
used as the collision gas at a flow rate of 0.15 mL min–1.
The QAs were identified and quantified based on m/z values determined in the MRM mode. The conditions
and fragmentation patterns are shown in Table 4.
+ Open protocol
+ Expand
6

Quantifying DNA and Detecting RNA Contamination

Check if the same lab product or an alternative is used in the 5 most similar protocols
To quantify DNA extracted from cells and to detect any potential RNA contamination, 5 μg aliquots of DNA were taken and digested to 2′-deoxynucleosides in the presence of phosphodiesterase I (120 mU), phosphodiesterase II (105 mU), DNase (35 U) and alkaline phosphatase (22 U) in 20 μL 10 mM Tris-HCl/15 mM ZnCl2 (pH 7.0) for 18 h at 37 °C. Quantitative analysis of dG was conducted by HPLC-UV using an Agilent Technologies 1100 HPLC system equipped with a diode array UV detector and an autosampler. Samples were loaded onto an Atlantis T3 C18 column (2.1 × 150 mm, 5 μm, from Waters Corporation, Milford, MA) eluted with a gradient of 5 mM ammonium formate, pH 4.0 (A) and methanol (B). Solvent composition was changed linearly from 3 to 30% B over 15 min, further increased to 80% B over 3 min, held at 80% B for 1 min, and returned to 3% B over 2 min, where it was kept for the final 8 min of the HPLC run. UV absorbance was monitored at 260 nm. With this method, dG eluted as a sharp peak at 11.7 min (Figure S-5). dG amounts were calculated from HPLC peak areas using a calibration curve constructed by injecting known amounts of dG.
+ Open protocol
+ Expand
7

Quantifying Antiretroviral Drugs in IVRs

Check if the same lab product or an alternative is used in the 5 most similar protocols
The in vivo release of TDF and FTC was determined from the amount of residual drug in used IVRs. Silicone segments containing one pod each were cut from the used IVRs. Each segment was cut open to expose the remaining pod residue, placed in 100 mL of 50% v/v aqueous methanol, and stirred overnight to dissolve the remaining drug in the pod. The concentration of TDF, TI (tenofovir isoproxil), TFV, and FTC in each solution was measured by high-performance liquid chromatography (HPLC) with UV detection (1100 Series, Agilent Technologies). Sample liquid chromatography-tandem mass spectrometry (LC-MS/MS) chromatogram overlays from a vaginal fluid sample collected during the TDF-FTC pod-IVR efficacy trial are shown (S1 Fig). A Waters (Milford, MA) Atlantis T3 C18 column (2.1 × 100 mm; 5 μm) controlled at 30°C was used as the stationary phase. The following gradient program was used (A, 1.0% v/v acetic acid and 3.0% v/v acetonitrile in water; B, acetonitrile): 1 min 100% A; 2 min ramp from 100:0 A:B to 75:25 A:B; 3 min hold at 75:25 A:B; 2 min ramp from 75:25 A:B to 100:0 A:B; 2 min hold at 100% A. The detection wavelength was 260 nm for TDF, TI, and TFV and 280 nm for FTC. Retention times were 8.29 min (TDF), 5.24 min (TI), 3.37 min (FTC), and 1.12 min (TFV). The method run times were 10 min.
+ Open protocol
+ Expand
8

UPLC-MS for Metabolite Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols
Eight microliter of the prepared sample was injected into a Waters Atlantis T3 C18 column (3 μm, 2.1 mm x 150 mm), and the eluent of the ultra-performance liquid chromatography (UPLC) (3000RSLCnano system, Dionex, Thermoscientific, N.W., Washington, D.C., USA) was directed to the ESI source of the mass spectrometer. The mobile phases consisted of a combination of solution A (0.1% formic acid in water) and solution B (0.1% formic acid in 100% acetonitrile). While maintaining a constant flow rate of 0.3 mL/min, the metabolites were eluted using linear gradients of 5–95% of B buffer from 0 to 14 min, and held at 95% of B buffer up to 17 min, after which it was decreased linearly to 5% at 17.1 min and held at 5% for 20 min until injection of the next analytical sample.
+ Open protocol
+ Expand
9

Quantification of Gemcitabine and dFdU in Plasma

Check if the same lab product or an alternative is used in the 5 most similar protocols
Plasma standards were prepared in microcentrifuge tubes by spiking 5 uL of Gemcitabine and dFdU into 190 uL of plasma containing 0.125 mg/mL THU. Floxuridine (10 μL) was added as an internal standard. Gemcitabine and dFdU were isolated by protein precipitation with the addition of 600 μL of acetonitrile. Analyte extraction was carried out via protein precipitation with the addition of 600 uL of acetonitrile. The samples were centrifuged for 5 minutes at 14000 RPM at 25°C. The supernatant was collected, dried under nitrogen, reconstituted with 200 uL of water and vortex mixed. Gemcitabine and dFdU extracted from plasma were quantified by reverse-phase HPLC with UV absorbance detection on a Shimadzu 10 series HPLC system. Separation of gemcitabine, dFdU and the internal standard floxuridine was achieved on an Atlantis T3 C18 column (Waters, 100 mm × 2.1 mm i.d., 5 μm particle diameter) fitted with a Brownlee NewGuard RP-18 pre-column (Chrom Tech, 15 mm × 3.2 mm i.d., 7 μm particle diameter). The mobile phase consisted of 10 mM potassium phosphate, pH 3.0 and methanol. The run was a gradient run starting out with 100% aqueous for 6 minutes, decreasing to 95% aqueous in 7 minutes and holding at 95% aqueous for 4 minutes followed by a high organic wash. The flow rate, the injection volume and detection wavelength were 0.4 ml/min, 20 μL and 272 nm, respectively.
+ Open protocol
+ Expand
10

Identification of Compounds in Subfraction

Check if the same lab product or an alternative is used in the 5 most similar protocols
The identification of the compounds in IV and VI sub-fractions was obtained by liquid chromatography mass spectrometry (LC-MS/MS) on a Q-Tof Premier mass spectrometer (Waters Corporation, Milford, MA, USA) coupled to an Alliance 2695 HPLC system (Waters Corporation, Milford, MA, USA) using the same parameters of a validated method previously described and employed for A. glabra samples [10 (link)]. In particular, a negative ionization mode was used to acquire the electrospray mass spectra data for a mass range m/z 100 to m/z 1000 in according to the present literature [67 (link),68 (link)]. An Atlantis T3 C18 column was used (Waters Corporation, Milford, USA, 100.00 × 2.10 mm; 3.00 µm particle size) at 40 °C. The mobile phases were 0.10% aqueous formic acid (solvent A) and 0.10% formic acid in acetonitrile (solvent B). The stepwise gradient from 10% to 90% solvent B was applied at flow rate of 300 µL/min for 25 min. Cone voltage and capillary voltage were set at 30 V and 3 kV, respectively. Argon was used as collision gas and the collision induced fragmentation (CID) of the analytes was achieved using 12 to 30 eV energy. The injection volume for all the samples was 3.00 µL.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!